Navigation Links
Theramed Secures Exclusive Canadian Distribution Rights for Two Novel Obstetrics Products from Glenveigh
Date:4/14/2011

MISSISSAUGA, Ontario, April 14, 2011 /PRNewswire/ -- Theramed Corporation ("Theramed") announces that it has obtained the exclusive distribution rights in Canada for the EBB® Complete Tamponade System and the JETTY® Vaginal Repair Balloon, two newly developed medical devices used to advance the practice of obstetrics, from Glenveigh International, LLC ("Glenveigh").  [Both] medical device products have been approved for sale by Health Canada, and Theramed will begin distributing these products immediately.

About the EBB® Complete Tamponade System

EBB® is a complete tamponade solution for the emergency of postpartum hemorrhage.  Designed by world-renowned maternal-fetal medicine specialists Michael A. Belfort and Gary A. Dildy, the EBB® balloon is made of a malleable yet extremely strong material, allowing EBB to expand and conform to any uterine shape. Ebb also features a vaginal balloon to control vaginal bleeding and act as an anchor to support the uterine balloon. External ports allow independent control of inflation, deflation, irrigation, and drainage.

About the JETTY® Vaginal Repair Balloon

JETTY® is indicated for use during episiotomy and vaginal laceration repair to temporarily prevent the postpartum discharge of fluids from the vagina in order to assist with the repair procedure.  JETTY® provides clarity and cleanliness for a timely, effective repair, and it eliminates the need for vaginal packing with gauze or sponges.

About Theramed Corporation

Theramed Corporation, headquartered in Mississauga, Ontario, is a specialty pharmaceutical company, focused on the development, acquisition, in-licensing, marketing, and distribution of medical products in Canada. The Company is dedicated to bringing new-to-market and well-established healthcare innovations to Canadian Physicians and Hospitals, be these Pharmaceuticals, Biotech products, or Medical Devices. The company currently markets Delatestryl®, Viroptic®, CollatampG® and FSME IMMUNE®.

About Glenveigh International, LLC

Glenveigh International is the subsidiary of Glenveigh Medical LLC responsible for its ex-U.S. business. Glenveigh is a life science and medical technology company focused on advancing the practice of obstetrics, with aspirations to rapidly become the market leader in the OB/GYN field. Formed in 2004 by a maternal-fetal medicine (MFM) specialist, Glenveigh is founded on the core mission of improving the lives of pregnant mothers and their babies.

http://www.theramed.com


'/>"/>
SOURCE Theramed Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. KellBenx Secures Exclusive Worldwide License With AdnaGen for Commercializing Patented Antibodies
2. MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film
3. Core Essence Secures $11.5 Million Series B Financing
4. CardioFocus Secures $5M Credit Facility with Silicon Valley Bank
5. Vystar® Corporation Secures a $3M Credit Facility to Fund Growth
6. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
7. PLC Systems Secures $4 Million in Financing
8. Biomatrica Secures Strategic Investment from IQT
9. Digital Assent Secures $2 Million Series A Financing to Grow PatientPad Point-of-Care Network
10. TechniScan Secures $10 Million Equity Financing Facility
11. Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017   Pulmatrix, Inc . (NASDAQ: PULM), a ... serious pulmonary diseases, today announced that it has added two ... and asthma to its Scientific Advisory Board . ... Richard B. Moss , MD, former chief of the Pediatric ... Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... , March 27, 2017 ... to reach USD 16.0 billion by 2025, according to ... growing prevalence of chronic diseases is anticipated to be ... analyzers, which thereby widens the scope for growth during ... and bariatric population, which is highly susceptible to chronic ...
(Date:3/27/2017)... BOSTON , March 27, 2017  Allergan ... and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical ... innovative therapies based upon tetracycline chemistry, announced that ... the treatment of moderate to severe acne met ... a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... of two biometric time and attendance tracking products: the new NCheck Cloud Bio ... Cloud Bio Attendance uses biometric face recognition to enable users to check in ...
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... , ... A minimally invasive porcelain veneer is increasing in ... of Dental Laboratories (NADL) is informing dentists about the benefits of minimally invasive ... laboratories and technicians that create these veneers. , According to National Board ...
(Date:3/28/2017)... Kennett Square, PA (PRWEB) , ... March 28, 2017 , ... ... reputation online and across a variety of business channels. , While many results ... aspects of any public relations program. , When it comes to measurement, firms ...
(Date:3/28/2017)... ... 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader ... women’s hair loss. Although hair transplant procedures can be seen as more of a ... can be two reasons a woman may see her hair thinning. , “We are ...
Breaking Medicine News(10 mins):